• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Pressure BioSciences ends 2009 on a high note

Pressure BioSciences ends 2009 on a high note

March 31, 2010 By MassDevice staff

PBIO logo

Pressure BioSciences Inc. (NSDQ:PBIO) ended 2009 in fine shape, posting increased revenues and narrower net losses, and began 2010 with a $500,000 boost — with another $1.5 million waiting in the wings.

The Easton, Mass.-based firm reported revenues of $1.2 million for the year ended Dec. 31, 2009, up 46.1 percent compared with $852,000 during 2008. Net losses for the year were $3.3 million, down 33.1 percent compared with $4.9 million during 2008.

Pressure BioScience’s corporate controller, Joseph Damasio Jr., said in prepared remarks that the improved results are partly due to a greatly reduced cash burn. Excluding about $660,000 in non-cash charges, PBIO went through an average of $635,000 per quarter, Damasio said, down 40.4 percent compared with $1.1 million per quarter in 2008.

Pressure BioSciences also said it landed about $500,000 from the second tranche of its Series B fundraising round, taking its total B-round raise to roughly $1.7 million.

And there’s more — potentially $1.5 million more — in the offing from the exercise of warrants issued in a February 2009 private placement, CEO Richard Schumacher told MassDevice. Investors have until April 27 to exercise the warrants.

"If all investors exercise their warrants, the company has the potential to receive a total of approximately $1.5 million dollars over the next month," Schumacher told us. "About $250,000 is already in from voluntary exercises, so about $1.25 million can still come in by April 27th."

Pressure BioSciences ended last year with about $1.6 million in cash and equivalents, nearly double the $868,000 it had at the end of the prior year. Schumacher said in prepared remarks that the company is in discussions "with several companies" about inking marketing, sales and distribution deals and that the company believes an agreement with one or more partners is likely this year.

Filed Under: Business/Financial News, Lab Instruments & Supplies, MassDevice Earnings Roundup, News Well Tagged With: Pressure BioSciences Inc.

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy